Neurological symptoms often develop gradually and may include: Paraesthesia : tingling or 'pins and needles' sensations, typically starting in the feet and hands Numbness : reduced sensation in the extremities, which may affect balance and coordination Burning pain : particularly in the feet, often worse at night Weakness : muscle weakness and difficulty walking Balance problems : unsteady gait and increased fall risk due to proprioceptive impairment Cognitive changes : memory problems, confusion, difficulty concentrating, and mood disturbances Haematological signs may accompany neurological symptoms and include fatigue, weakness, pallor, and shortness of breath due to megaloblastic anaemia
The standard KLOW dosage is 3.2 mg (10 units) per injection: daily during the activation phase in weeks 14, 5x per week during the remodeling phase in weeks 58, and 2-3x per week during maintenance in weeks 912
With increasing weight loss, osteoporosis risk increased in both groups, and the GLP-1 risks were generally similar to or higher than the non-GLP-1 weight loss medication risks
Visit our website today to schedule a consultation and take the first step toward a healthier, more confident you.
Tirzepatida reduce triglicridos aproximadamente 15-25% y semaglutida 12-17% en estudios clnicos
Key Questions Answered If my BMI doesnt qualify for GLP-1s, is Naltrexone + Bupropion helpfuland what labs matter first